Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Forest Laboratories, Inc. (NY: FRX)
39.53 USD  UNCHANGED
Official Closing Price  /  Updated: 6:40 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 4,032,566
Open 38.01
Bid (Size) 39.70 (100)
Ask (Size) 41.00 (300)
Prev. Close 39.53
Today's Range 38.01 - 39.67
52wk Range 31.28 - 39.09
Shares Outstanding 266,284,246
Dividend Yield N/A
Top News
More News
REFILE-UPDATE 1-Forest Labs' longtime CEO Solomon to step down at year-end
May 23, 2013
May 23 (Reuters) - Forest Laboratories Inc said Howard Solomon, its chief executive of more than 35 years, will retire at the end of this year, capping a tenure that saw the company morph from a small... Read More
category companyNews
from Reuters: Company News
Oakmark Fund Buys Forest Laboratories, DirecTV, UnitedHealth, Apple
May 23, 2013
Oakmark Fund Buys Forest Laboratories, DirecTV, UnitedHealth, Apple Read More
category NYSE:BAC , NASD:AAPL , NYSE:FRX , and 2 more.
from Forbes Real Time

More News
Read More
Forest Labs (FRX) CEO to Retire at End of Year
May 23, 2013
from StreetInsider.com News Articles
Forest Laboratories Provides Update on Succession Planning
May 23, 2013
from Business Wire News Releases
Will Ranbaxy Labs Be Excluded From Medicare And Medicaid?
May 22, 2013
category RBXY:NATLINDIA , NYSE:FRX
from Forbes Real Time
Bearish Moving Average Cross by Forest Laboratories (FRX)
May 20, 2013
from Comtex SmarTrend® News Briefs
Pharma M&A – Actavis to Acquire Warner Chilcott
May 20, 2013
category Benzinga , Global , VRX , and 8 more.
from Latest Articles from Benzinga.com
Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference
May 17, 2013
from Business Wire News Releases
Forest Labs Will Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
May 16, 2013
category Benzinga , FRX , News
from Latest Articles from Benzinga.com
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
May 16, 2013
from Business Wire News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here